Replidyne, Inc. – Robert Thatcher 2106 Arnold Palmer Drive Blaine, MN 55449 Re: Separation Agreement and Release Dear Bob: (August 25th, 2016)
As we discussed with you, your employment with Cardiovascular Systems, Inc. ("CSI" or the "Company") will end effective at the close of business on May 25, 2016. The purpose of this Separation Agreement and Release letter ("Agreement") is to set forth the specific Salary and Wage Continuation Benefits and benefits CSI will provide to you in keeping with the CSI Amended and Restated Executive Officer Severance Plan dated February 27, 2015 (the "Severance Plan") in exchange for your agreement to the terms and conditions of this Agreement. Please note that you may not sign this Agreement until May 25, 2016.
Replidyne, Inc. – Fiscal 2016 Executive Officer Bonus Plan and Equity Compensation (August 27th, 2015)
For the twelve month period ending June 30, 2016, each executive officer of Cardiovascular Systems, Inc. (the "Company") is eligible to receive cash incentive compensation pursuant to the Fiscal 2016 Executive Officer Bonus Plan (the "Bonus Plan") as follows:
Replidyne, Inc. – Fiscal 2015 Executive Officer Bonus Plan and Equity Compensation (August 28th, 2014)
For the twelve month period ending June 30, 2015, each executive officer of Cardiovascular Systems, Inc. (the "Company") is eligible to receive cash incentive compensation pursuant to the Fiscal 2015 Executive Officer Bonus Plan (the "Bonus Plan") as follows:
Replidyne, Inc. – Contract (September 11th, 2013)
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Fiscal Year 2012 Executive Officer Base Salaries (September 12th, 2011)
The Companys executive officers are scheduled to receive the following annual base salaries for the fiscal year ending June 30, 2012 in their current positions:
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Executive Officer Severance Plan (September 28th, 2010)
Effective June 28, 2010, the Company adopted the Cardiovascular Systems, Inc. Executive Officer Severance Plan. The Severance Plan applies initially to: David L. Martin, President and Chief Executive Officer; Laurence L. Betterley, Chief Financial Officer; James E. Flaherty, Chief Administrative Officer and Secretary; Robert J. Thatcher, Executive Vice President; Brian Doughty, Vice President of Commercial Operations; Paul A. Tyska, Vice President of Business Development; Paul A. Koehn, Vice President of Manufacturing; and Scott W. Kraus, Vice President of Sales. Under the Severance Plan, if the Company terminates an executive without cause or due to a reduction in force, as defined in the plan, the executive will receive certain severance benefits during the severance period. The severance period is 18 months for the Chief Executive Officer; 15 months for the Chief Financial Officer, and 12 months for all other executives. For purposes of the Severance Plan, cause is generally defined
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Fiscal Year 2011 Executive Officer Base Salaries (September 28th, 2010)
The Companys executive officers are scheduled to receive the following annual base salaries for the fiscal year ending June 30, 2011 in their current positions:
Replidyne, Inc. – Corporate Job Creation Agreement (September 29th, 2009)
This Corporate Job Creation Agreement (Agreement) is entered into as of June ___, 2009, by and between the Pearland Economic Development Corporation of Pearland, Texas (the PEDC), and Cardiovascular Systems Inc., having its principal place of business at 650 Campus Drive, St Paul Minnesota (the Company), for the establishment of a manufacturing and distribution facility in Pearland, Texas (hereinafter collectively referred to as the Parties).
Replidyne, Inc. – Cardiovascular Systems, Inc. Summary of Fiscal Year 2009 Executive Officer Annual Cash Incentive Compensation (May 14th, 2009)
Effective February 25, 2009, the Companys board of directors adopted an executive officer cash incentive compensation plan applicable to the six-month period ended June 30, 2009. This plan conditions the payment of incentive compensation to all participants upon the Companys achievement of revenue and adjusted EBITDA financial goals. Target bonus amounts are split evenly between these two goals. None of the Companys officers is subject to individual goals under this plan. No plan participant will receive a bonus unless the Company achieves certain minimum adjusted EBITDA goals.
Csi Minnesota, Inc. – Amendment No. 2 to Investors Rights Agreement (January 22nd, 2008)
THIS AMENDMENT NO. 2 TO INVESTORS RIGHTS AGREEMENT is entered into effective this 19th day of September, 2007 (this Amendment No. 2), by and among Cardiovascular Systems, Inc., a Minnesota Corporation (the Company) , the Series A-1 Convertible Preferred Stockholders listed on Exhibit A hereto (Series A-1 Investors), and the Investors signatory hereto.